Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved..
Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a, and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P) and ribavirin (R). Prevalence of Q80K among G1 patients may vary geographically. Q80K prevalence in the North-American G1 population in a recent study was 34%. We conducted a post hoc meta-analysis of Q80K polymorphism prevalence among HCV G1-infected patients enrolled in simeprevir and telaprevir Phase II/III studies. Baseline HCV NS3/4A protease sequences were analysed by population sequencing to determine Q80K prevalence. Overall, of 3349 patients from 25 countries in the European region analysed, 35.8%, 63.8% and 0.3% of patients had G1a, G1b and other/unknown HCV G1 subtypes, respectively. Q80K was detected at baseline in 7.5% of HCV G1 patients overall. Examination by subtype showed that 19.8%, 0.5% and 18.2% of patients with G1a, G1b and other/unknown HCV G1 subtypes had the Q80K polymorphism, respectively. Among countries in the European region with sequencing data available for either ⩾20 patients with G1a and/or ⩾40 G1 patients overall, the Q80K prevalence in G1 ranged from 0% in Bulgaria to 18.2% in the UK. Q80K prevalence also varied within G1a across different countries. HCV subtype 1a was correctly determined in 99% of patients by the LiPA v2 assay. A low overall prevalence of Q80K was observed in HCV G1-infected patients in the European region, compared with North America. However, the prevalence varied by country, due to differing ratios of G1a/G1b and differing Q80K prevalence within the G1a populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:116 |
|---|---|
| Enthalten in: |
Antiviral research - 116(2015) vom: 01. Apr., Seite 10-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sarrazin, Christoph [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2015 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.antiviral.2015.01.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM245589627 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM245589627 | ||
| 003 | DE-627 | ||
| 005 | 20231224141213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2015.01.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0818.xml |
| 035 | |a (DE-627)NLM245589627 | ||
| 035 | |a (NLM)25614456 | ||
| 035 | |a (PII)S0166-3542(15)00004-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sarrazin, Christoph |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2015 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Hepatitis C virus (HCV) NS3 polymorphism Q80K is mainly found in patients with HCV genotype (G) 1a, and has been associated with a reduced treatment response to simeprevir with pegylated interferon (P) and ribavirin (R). Prevalence of Q80K among G1 patients may vary geographically. Q80K prevalence in the North-American G1 population in a recent study was 34%. We conducted a post hoc meta-analysis of Q80K polymorphism prevalence among HCV G1-infected patients enrolled in simeprevir and telaprevir Phase II/III studies. Baseline HCV NS3/4A protease sequences were analysed by population sequencing to determine Q80K prevalence. Overall, of 3349 patients from 25 countries in the European region analysed, 35.8%, 63.8% and 0.3% of patients had G1a, G1b and other/unknown HCV G1 subtypes, respectively. Q80K was detected at baseline in 7.5% of HCV G1 patients overall. Examination by subtype showed that 19.8%, 0.5% and 18.2% of patients with G1a, G1b and other/unknown HCV G1 subtypes had the Q80K polymorphism, respectively. Among countries in the European region with sequencing data available for either ⩾20 patients with G1a and/or ⩾40 G1 patients overall, the Q80K prevalence in G1 ranged from 0% in Bulgaria to 18.2% in the UK. Q80K prevalence also varied within G1a across different countries. HCV subtype 1a was correctly determined in 99% of patients by the LiPA v2 assay. A low overall prevalence of Q80K was observed in HCV G1-infected patients in the European region, compared with North America. However, the prevalence varied by country, due to differing ratios of G1a/G1b and differing Q80K prevalence within the G1a populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a NS3/4A protease | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Q80K polymorphism | |
| 650 | 4 | |a Simeprevir | |
| 650 | 4 | |a Virology | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a NS3 protein, hepatitis C virus |2 NLM | |
| 650 | 7 | |a Oligopeptides |2 NLM | |
| 650 | 7 | |a Viral Nonstructural Proteins |2 NLM | |
| 650 | 7 | |a telaprevir |2 NLM | |
| 650 | 7 | |a 655M5O3W0U |2 NLM | |
| 650 | 7 | |a Simeprevir |2 NLM | |
| 650 | 7 | |a 9WS5RD66HZ |2 NLM | |
| 700 | 1 | |a Lathouwers, Erkki |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Daems, Bjorn |e verfasserin |4 aut | |
| 700 | 1 | |a Buelens, Annemie |e verfasserin |4 aut | |
| 700 | 1 | |a Witek, James |e verfasserin |4 aut | |
| 700 | 1 | |a Wyckmans, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Fevery, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Verbinnen, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Ghys, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Schlag, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Baldini, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a De Meyer, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Lenz, Oliver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antiviral research |d 1983 |g 116(2015) vom: 01. Apr., Seite 10-6 |w (DE-627)NLM012601756 |x 1872-9096 |7 nnns |
| 773 | 1 | 8 | |g volume:116 |g year:2015 |g day:01 |g month:04 |g pages:10-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.antiviral.2015.01.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 116 |j 2015 |b 01 |c 04 |h 10-6 | ||